Vizora日本語

Human Metabolome TechnologiesHuman Metabolome Technologies, Inc.6090東証スタンダードサービス業FY ending Jun 2026, consolidated, J-GAAP

Human Metabolome Technologies FY ending Jun 2021 results

About 50% of Human Metabolome Technologies's sales come from Metabolome analysis, with Researchsupport analysis and Biochemical marker making up much of the rest.

Out of every ¥100 of sales, about ¥4 is left as operating profit.

Revenue changed +0.5% from the prior year, and it swung back to an operating profit.

Revenue and profit pattern

Turned profitable

What changed from last year

FY ending Jun 2020 → FY ending Jun 2021

Revenue
+0.5%¥1.12B → ¥1.12B
Gross profit
-5.9%¥856.7M → ¥806M
Operating income
Back to profit-¥17M → ¥39.4M
Net income attributable to owners
Back to profit-¥47.8M → ¥58.2M
Operating cash flow
-118.6%¥184.1M → -¥34.2M
Free cash flow
-141.6%¥149.2M → -¥62M

Where the money goes

FY ending Jun 2020 → FY ending Jun 2021

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

Where ¥100 of sales goes

For every ¥100 Human Metabolome Technologies sells, how much goes where, and how much is kept.

FY ending Jun 2021
Cost of sales
¥28
SG&A
¥68
Operating profit
¥4
Net profit kept
¥5

Annual margin trends

Gross margin71.7%
FY ending Jun 2020: 76.6%76.6%FY ending Jun 2021: 71.7%71.7%FY20FY21
Operating margin3.5%
FY ending Jun 2020: -1.5%-1.5%FY ending Jun 2021: 3.5%3.5%FY20FY21
Net margin5.2%
FY ending Jun 2020: -4.3%-4.3%FY ending Jun 2021: 5.2%5.2%FY20FY21

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Jun 2021
  • Metabolome analysis¥1.12B
    50%
    Op. margin 37.8%
  • Researchsupport analysis¥1.12B
    50%
    Op. margin 12.6%
  • Biochemical marker¥4.5M
    0%
    Op. margin -1578.7%
  • healthcare analysis¥4.5M
    0%
    Op. margin -2279.4%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (5)

  • EDINET (FSA Japan)

    有価証券報告書－第22期(2024/07/01－2025/06/30)

    ID S100WPSX2025-09-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第21期(2023/07/01－2024/06/30)

    ID S100UE9D2024-09-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第20期(2022/07/01－2023/06/30)

    ID S100RW1Z2023-09-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第19期(令和3年7月1日－令和4年6月30日)

    ID S100P8152022-09-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第18期(令和2年7月1日－令和3年6月30日)

    ID S100MHKD2021-09-27Open

Extracted from XBRL: 45 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image